Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-09-21, Stock:LLY, The news for the past five days is as follows:
2018-09-14: NEWS1: Eli Lilly Is Selling More Shares of This Biopharma Firm.NEWS2: AstraZeneca's Lumoxiti Gets FDA Nod for Hairy Cell Leukemia.NEWS3: AstraZeneca's Lumoxiti Gets FDA Nod for Hairy Cell Leukemia.NEWS4: Roche's Child Arthritis Drug's New Formulation Gets FDA Nod.NEWS5: Roche's Child Arthritis Drug's New Formulation Gets FDA Nod.NEWS6: Pharma Stock Roundup: AZN&apos;s Leukemia Drug Wins FDA Nod, MRK&apos;s Keytruda in Focus.NEWS7: Roche&apos;s Child Arthritis Drug&apos;s New Formulation Gets FDA Nod.NEWS8: AstraZeneca&apos;s Lumoxiti Gets FDA Nod for Hairy Cell Leukemia.
2018-09-17: NEWS1: Glaxo Seeks EU Approval for Two-Drug Regimen in First-Line HIV.NEWS2: Analysts Raise Ratings on Teva Stock on Ajovy’s FDA Approval.NEWS3: How Pharmaceutical ETFs Have Performed in 2018.NEWS4: Competition Dynamics for Ajovy—Teva’s Migraine Drug.NEWS5: Allergan Frown Lines Study Passes Test on Higher Botox Dose.NEWS6: Allergan Frown Lines Study Passes Test on Higher Botox Dose.NEWS7: Teva's (TEVA) Migraine Drug Ajovy Receives FDA Approval.NEWS8: Teva's (TEVA) Migraine Drug Ajovy Receives FDA Approval.NEWS9: These Pharmaceutical Stocks Have Surpassed the S&P 500 in 2018.NEWS10: Teva stock surges 7% after FDA approves migraine medication.
2018-09-18: NEWS1: Bayer (BAYRY) Focuses on Acquisitions, Competition a Concern.NEWS2: Bayer (BAYRY) Focuses on Acquisitions, Competition a Concern.NEWS3: Does Ajovy's Approval Make Teva a Pain-Free Stock to Buy?.NEWS4: Does Ajovy's Approval Make Teva a Pain-Free Stock to Buy?.NEWS5: Bayer (BAYRY) Focuses on Acquisitions, Competition a Concern.NEWS6: Exploring Pharmaceutical Stocks’ Revenue Growth Rates.NEWS7: Is Galapagos NV a Buy Now?.NEWS8: Is Galapagos NV a Buy Now?.NEWS9: A Look at the Dividends Paid by Pharma Stocks in 2018.NEWS10: Glaxo Seeks EU Approval for Two-Drug Regimen in First-Line HIV.NEWS11: Glaxo Seeks EU Approval for Two-Drug Regimen in First-Line HIV.
2018-09-19: NEWS1: Lilly's Elanco animal health unit's IPO priced at $24/share.NEWS2: Elanco Animal Health prices IPO above expected range.NEWS3: Elanco Announces Pricing of Initial Public Offering.NEWS4: J&J Files NDA for Erdafitinib in Urothelial Cancer Indication.NEWS5: J&J Files NDA for Erdafitinib in Urothelial Cancer Indication.NEWS6: Lilly's Elanco Rises After $1.5 Billion Animal-Health IPO.NEWS7: Lilly's Elanco Raises $1.5 Billion in Animal-Health IPO.NEWS8: J&J Files NDA for Erdafitinib in Urothelial Cancer Indication.NEWS9: Pharma Stocks: Pfizer’s Revenue Trend and 2018 Estimates.NEWS10: Novo Nordisk to Restructure R&D Unit & Lay Off 400 Staff.NEWS11: Novo Nordisk to Restructure R&D Unit & Lay Off 400 Staff.NEWS12: Novo Nordisk to Restructure R&D Unit & Lay Off 400 Staff.NEWS13: Pharma Stocks in Review: A Valuation Comparison.
2018-09-20: NEWS1: Animal health firm Elanco surges 41 percent on debut.NEWS2: Eli Lilly Prices Animal Health Unit IPO at $24 Per Share.NEWS3: Eli Lilly Prices Animal Health Unit IPO at $24 Per Share.NEWS4: Elanco Animal Health stock soars more than 35% in trading debut.NEWS5: Eli Lilly Prices Animal Health Unit IPO at $24 Per Share.NEWS6: Elanco CEO on IPO, animal health focus.NEWS7: Pharma Stocks: GlaxoSmithKline’s Revenue Trend and 2018 Estimates.NEWS8: Pharma Stocks: Allergan’s Revenue Trend and 2018 Estimates.NEWS9: Elanco’s $1.7 billion IPO looks too pricey, and here’s why.NEWS10: Elanco’s $1.6 billion IPO looks too pricey, and here’s why.NEWS11: D-Day Nearing For Antares Pharma.NEWS12: D-Day Nearing For Antares Pharma.

Answer: Rise